首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   83篇
  免费   9篇
  国内免费   1篇
儿科学   3篇
基础医学   6篇
口腔科学   5篇
临床医学   17篇
内科学   19篇
神经病学   4篇
特种医学   3篇
外科学   26篇
预防医学   6篇
眼科学   1篇
药学   2篇
肿瘤学   1篇
  2023年   5篇
  2021年   5篇
  2020年   3篇
  2019年   3篇
  2018年   6篇
  2017年   3篇
  2016年   1篇
  2015年   2篇
  2014年   6篇
  2013年   6篇
  2012年   9篇
  2011年   9篇
  2010年   3篇
  2009年   4篇
  2008年   5篇
  2007年   4篇
  2006年   4篇
  2005年   4篇
  2004年   3篇
  2003年   6篇
  2002年   2篇
排序方式: 共有93条查询结果,搜索用时 0 毫秒
91.

Background

Sulfonylureas are oral glucose-lowering medications positioned as a second-line therapy for type 2 diabetes. Evidence relating them to cognitive decline has been mixed. The objective was to determine whether sulfonylurea use was associated with a differential risk of dementia compared with dipeptidyl peptidase-4 (DPP4) inhibitor use.

Methods

Using administrative data from residents in Ontario, Canada, adults aged ≥66 years who were new users of a sulfonylurea or a DPP4 inhibitor from June 14, 2011, to March 31, 2021 entered this population-based retrospective cohort study. Dementia was ascertained using a validated algorithm for Alzheimer's disease and related dementias. Propensity-score weighted Cox proportional hazards models were used to obtain adjusted hazard ratios (aHR) and confidence intervals (CI) for time to incident dementia. The observation window started at 1 year after cohort entry to mitigate protopathic bias due to delayed diagnosis. The primary analysis used an intention-to-treat exposure definition. A separate propensity-score weighted analysis was conducted to explore within-class differences in dementia risk among sulfonylurea new users selected from the primary cohort.

Results

Among 107,806 DPP4 inhibitor new users and 37,030 sulfonylurea new users, sulfonylureas compared with DPP4 inhibitors were associated with a higher risk of dementia (18.4/1000 person-years; aHR [95% CI] = 1.09 [1.04–1.15]) over a mean follow-up of 4.82 years from cohort entry. Glyburide compared to gliclazide exhibited a higher dementia risk (aHR [95% CI] = 1.17 [1.03–1.32]).

Conclusion

New use of a sulfonylurea especially glyburide was associated with a higher dementia risk compared with new use of a DPP4 inhibitor in older adults with diabetes.  相似文献   
92.

Aims

To assess post-initiation predictors of discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared to dipeptidyl-peptidase-4 (DPP-4) inhibitors in the United Kingdom.

Materials and Methods

We conducted a comparative population-based retrospective cohort study using primary care data from the UK Clinical Practice Research Datalink (CPRD) with linked data to hospital and death records. We included new metformin users who initiated either SGLT2 inhibitors or DPP-4 inhibitors between January 2013 and October 2019. The main outcome was treatment discontinuation, defined as the first 90-day gap after the estimated treatment end date. We used a series of extended Cox models to assess which time-dependent predictors were associated with treatment discontinuation. To test if the hazard ratio of discontinuation for each predictor was statistically different between SGLT2 and DPP-4 inhibitors, an exposure-predictor interaction term was added to each model.

Results

There were 2550 new users of SGLT2 inhibitors and 8195 new users of DPP-4 inhibitors. Approximately 69% of SGLT2 inhibitor and 74% of DPP-4 inhibitor users had discontinued treatment by the end of follow-up. Occurrence of fractures after treatment initiation was a significant predictor of discontinuation of SGLT2 inhibitors (hazard ratio [HR] 4.13, 95% confidence interval [CI] 2.12-8.06) but not DPP-4 inhibitors (HR 0.93, 95% CI 0.79-1.11). The rate of treatment discontinuation was significantly higher for those with low estimated glomerular filtration rate and minimal contact with the healthcare system. Efficacy endpoints, such as heart failure and glycated haemoglobin level, were not associated with treatment discontinuation.

Conclusions

Our findings reflect some discrepancy between the available evidence and prescribing behaviour for SGLT2 inhibitors.  相似文献   
93.
We propose and analyze a new family of nonconforming finite elements for the three-dimensional quad-curl problem. The proposed finite element spaces are subspaces of $\boldsymbol{H}$(curl), but not of $\boldsymbol{H}$(grad curl), which are different from the existing nonconforming ones [10,12,13]. The well-posedness of the discrete problem is proved and optimal error estimates in discrete $\boldsymbol{H}$(grad curl) norm, $\boldsymbol{H}$(curl) norm and $L^2$ norm are derived. Numerical experiments are provided to illustrate the good performance of the method and confirm our theoretical predictions.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号